A Phase 3 interventional study of adalimumab and placebo for adalimumab in Enthesitis Related Arthritis (ERA), sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-07-12.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by AbbVie — 2 open to participants now, 3 under way, 2 of them phase 3. Arthritis, Juvenile · AbbVie.
Among the 10 studies in Arthritis, Juvenile by AbbVie, this one is the only one that started in 2010, is one of 4 in phase 3, and was the 3rd registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →2 of the 10 studies in Arthritis, Juvenile by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Canada and 6 more countries
Ages 5–17
AbbVie · Sites in United States, Argentina, Australia and 14 more countries
Ages 1–17
By country, each count listing its studies:
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 46 across the 5 interventional studies, 70 across the 5 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo for adalimumab every other week (eow) for 12 weeks.
Biological: placebo for adalimumab
Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.
Biological: adalimumab
Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.
Biological: adalimumab
Adalimumab solution for subcutaneous injection.
Also known as: ABT-D2E7, Humira
Placebo for adalimumab solution for subcutaneous injection.
Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12
A joint assessment was recorded at all study visits to assess the number of active joints. A total of 72 joints were assessed for swelling not due to deformity or joints with loss of motion (LOM) plus pain and/or tenderness. Total possible scores ranges from 0 (no active joints) to 72 (all active joints). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Last Observation Carried Forward (LOCF) was used for missing data.
Time frame: Baseline and Week 12
Number of Sites of Enthesitis: Change From Baseline to Week 12
The presence of enthesitis was assessed by pressure at 35 anatomical locations. Enthesitis was classifed as either present or absent. Scores range from 0 to 35, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.
Time frame: Baseline and Week 12
Tender Joint Count (TJC72): Change From Baseline to Week 12
Seventy-two joints were assessed by pressure on physical examination. Joint tenderness was classified as either present or absent. Scores range from 0 to 72, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.
Time frame: Baseline and Week 12
Swollen Joint Count (SJC68): Change From Baseline to Week 12
Sixty-eight joints were assessed by physical examination. Joint swelling was classified as present or absent. Scores range from 0 to 68, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response (ACR Pedi30)
The ACR Pedi30 response is defined as ≥30% improvement in at least 3 of 6 juvenile rheumatoid arthritis (JRA) core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. Non-responder imputation (NRI) was used for missing data.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 50% Response (ACR Pedi50)
The ACR Pedi50 response is defined as ≥50% improvement in at least 3 of 6 JRA core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. NRI was used.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 70% Response (ACR Pedi70)
The ACR Pedi70 response is defined as ≥70% improvement in at least 3 of 6 JRA core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. Non-responder imputation NRI was used.
Time frame: Baseline and Week 12
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either probably related to study drug, possibly related to study drug, probably not related, or not related to study drug. For more details on adverse events please see the AE section below.
Time frame: Treatment-emergent AEs (TEAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 212 weeks)
The study included a 30-day screening period.
| Milestone | Double-blind Placebo EOW | Double-blind Adalimumab EOW | Open-label Adalimumab EOW |
|---|---|---|---|
| Started | 15 | 31 | 0 |
| Completed | 15 | 31 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Double-blind Placebo EOW | Double-blind Adalimumab EOW | Open-label Adalimumab EOW |
|---|---|---|---|
| Started | 0 | 0 | 46 |
| Completed | 0 | 0 | 29 |
| Not completed | 0 | 0 | 17 |
| Withdrew: Adverse event | 0 | 0 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Remission | 0 | 0 | 4 |
| Withdrew: Irregular compliance | 0 | 0 | 1 |
A joint assessment was recorded at all study visits to assess the number of active joints. A total of 72 joints were assessed for swelling not due to deformity or joints with loss of motion (LOM) plus pain and/or tenderness. Total possible scores ranges from 0 (no active joints) to 72 (all active joints). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Last Observation Carried Forward (LOCF) was used for missing data.
| percent change | Double-blind Placebo EOW | Double-blind Adalimumab EOW |
|---|---|---|
| Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12 | -11.6 ± 100.5 | -62.6 ± 59.53 |
The presence of enthesitis was assessed by pressure at 35 anatomical locations. Enthesitis was classifed as either present or absent. Scores range from 0 to 35, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.
| sites of enthesitis | Double-blind Placebo EOW | Double-blind Adalimumab EOW |
|---|---|---|
| Baseline | 7.8 ± 7.49 | 8.3 ± 8.89 |
| Week 12 | 5.1 ± 8.92 | 3.9 ± 6.60 |
| Change from Baseline to Week 12 | -2.7 ± 4.98 | -4.4 ± 6.20 |
Seventy-two joints were assessed by pressure on physical examination. Joint tenderness was classified as either present or absent. Scores range from 0 to 72, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.
| units on a scale | Double-blind Placebo EOW | Double-blind Adalimumab EOW |
|---|---|---|
| Baseline | 11.9 ± 9.34 | 13.4 ± 10.49 |
| Week 12 | 7.5 ± 8.06 | 5.5 ± 8.77 |
| Change from Baseline to Week 12 | -4.5 ± 8.97 | -7.9 ± 8.25 |
Sixty-eight joints were assessed by physical examination. Joint swelling was classified as present or absent. Scores range from 0 to 68, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. LOCF was used.
| units on a scale | Double-blind Placebo EOW | Double-blind Adalimumab EOW |
|---|---|---|
| Baseline | 5.2 ± 3.69 | 6.7 ± 7.30 |
| Week 12 | 2.8 ± 2.83 | 3.2 ± 7.27 |
| Change from Baseline to Week 12 | -2.4 ± 4.66 | -3.5 ± 5.61 |
The ACR Pedi30 response is defined as ≥30% improvement in at least 3 of 6 juvenile rheumatoid arthritis (JRA) core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. Non-responder imputation (NRI) was used for missing data.
| percentage of participants | Double-blind Placebo EOW | Double-blind Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response (ACR Pedi30) | 60.0 | 71.0 |
The ACR Pedi50 response is defined as ≥50% improvement in at least 3 of 6 JRA core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. NRI was used.
| percentage of participants | Double-blind Placebo EOW | Double-blind Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 50% Response (ACR Pedi50) | 40.0 | 67.7 |
The ACR Pedi70 response is defined as ≥70% improvement in at least 3 of 6 JRA core set criteria with no more than 1 of the 6 criteria with \>30% worsening. The 6 variables for the JRA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's overall well-being, number of active joints (joints with swelling not due to deformity or joints LOM plus pain and/or tenderness), number of joints with LOM, Childhood Health Assessment Questionnaire (CHAQ), and high sensitivity C-reactive protein (hs CRP). Baseline is the last value prior to the first dose of study drug. Non-responder imputation NRI was used.
| percentage of participants | Double-blind Placebo EOW | Double-blind Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 70% Response (ACR Pedi70) | 20.0 | 54.8 |
An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either probably related to study drug, possibly related to study drug, probably not related, or not related to study drug. For more details on adverse events please see the AE section below.
| participants | Double-blind Placebo EOW | Double-blind Adalimumab EOW | Any Adalimumab |
|---|---|---|---|
| Any TEAE | 8 | 21 | 46 |
| TEAEs at least possibly related to study drug | 4 | 9 | 29 |
| Any severe TEAE | 0 | 0 | 7 |
| TESAE | 0 | 1 | 10 |
| Any TEAE Leading to Discontinuation of Study | 0 | 0 | 7 |
| Death | 0 | 0 | 0 |
Collected over Treatment-emergent AEs (TEAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 212 weeks); SAEs were collected from the time informed consent was obtained (up to 216 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Placebo EOW | — | 0/15 (0%) | 8/15 (53.3%) |
| Double-blind Adalimumab EOW | — | 1/31 (3.2%) | 21/31 (67.7%) |
| Any Adalimumab | — | 10/46 (21.7%) | 46/46 (100%) |
| Event | Double-blind Placebo EOW | Double-blind Adalimumab EOW | Any Adalimumab |
|---|---|---|---|
| JUVENILE IDIOPATHIC ARTHRITISMusculoskeletal and connective tissue disorders | 0/15 | 0/31 | 2/46 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/15 | 1/31 | 1/46 |
| HEADACHENervous system disorders | 0/15 | 1/31 | 1/46 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 0/15 | 0/31 | 1/46 |
| PAINGeneral disorders | 0/15 | 0/31 | 1/46 |
| APPENDICITISInfections and infestations | 0/15 | 0/31 | 1/46 |
| DISSEMINATED TUBERCULOSISInfections and infestations | 0/15 | 0/31 | 1/46 |
| PNEUMONIAInfections and infestations | 0/15 | 0/31 | 1/46 |
| URINARY TRACT INFECTIONInfections and infestations | 0/15 | 0/31 | 1/46 |
| BURNS SECOND DEGREEInjury, poisoning and procedural complications | 0/15 | 0/31 | 1/46 |
| Event | Double-blind Placebo EOW | Double-blind Adalimumab EOW | Any Adalimumab |
|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/15 | 3/31 | 16/46 |
| NASOPHARYNGITISInfections and infestations | 1/15 | 0/31 | 11/46 |
| HEADACHENervous system disorders | 0/15 | 3/31 | 10/46 |
| DIARRHOEAGastrointestinal disorders | 0/15 | 1/31 | 8/46 |
| GASTROENTERITISInfections and infestations | 0/15 | 2/31 | 8/46 |
| PHARYNGITISInfections and infestations | 0/15 | 1/31 | 7/46 |
| PHARYNGOTONSILLITISInfections and infestations | 0/15 | 0/31 | 7/46 |
| ABDOMINAL PAINGastrointestinal disorders | 0/15 | 1/31 | 6/46 |
| PYREXIAGeneral disorders | 0/15 | 0/31 | 6/46 |
| JUVENILE IDIOPATHIC ARTHRITISMusculoskeletal and connective tissue disorders | 1/15 | 0/31 | 6/46 |
Intent-to-treat (ITT) population: All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Double-blind Placebo EOW | Double-blind Adalimumab EOW | Total |
|---|---|---|---|
| Mean | 11.9 ± 2.85 | 13.4 ± 2.86 | 12.9 ± 2.92 |
| Sex: Female, Male(Participants) | Double-blind Placebo EOW | Double-blind Adalimumab EOW | Total |
|---|---|---|---|
| Female | 6 | 9 | 15 |
| Male | 9 | 22 | 31 |
No study locations are listed for this record.
The record gives a start of Sep 2010, a primary completion of Nov 2012 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →